EAM
RCKT icon

Exome Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Exome Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-159,552
Closed -$2.01M – 77
2024
Q4 		$2.01M Buy
+159,552
New +$2.4M 1.51% 29
2024
Q1 		– Sell
-91,800
Closed -$2.75M – 69
2023
Q4 		$2.75M Buy
+91,800
New +$2.03M 2.72% 14

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exome Asset Management's RCKT Position: Q1 2025 in Review

Exome Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 159,552 shares — an estimated $2.01M sold.

Exome Asset Management first reported a position in RCKT in Q4 2023 and held it in 2 quarters. The position peaked at $2.75M in Q4 2023. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Exome Asset Management reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 159,552 Rocket Pharmaceuticals shares in Q1 2025, an estimated $2.01M.
  • Exome Asset Management first reported a position in Rocket Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Exome Asset Management's Rocket Pharmaceuticals position peaked at $2.75M in Q4 2023.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.